Clinical Trial Update: GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2, open-label, single-center study assessed GE-148 (18F) PET imaging to detect localized prostate cancer; the trial was terminated with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• GE-148 (18F) Injection for PET Imaging (GE-148)

Snippet

Sponsor: GE Healthcare | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2013-11-21